• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intravesical sequential combination of epirubicin and interferon alpha-2b in patients affected by superficial transitional cell carcinoma of the bladder. Results of a pilot study at Palermo University and proposal of a basic research.

作者信息

Serretta V, Corselli G, Pavone C, Pizzuto Antinoro S A, Pavone-Macaluso M

机构信息

Istituto Policattedra di Materie Urologiche, Facoltà di Medicina e Chirurgia, Università di Palermo, Italy.

出版信息

Prog Clin Biol Res. 1991;370:185-93.

PMID:1924449
Abstract
摘要

相似文献

1
Intravesical sequential combination of epirubicin and interferon alpha-2b in patients affected by superficial transitional cell carcinoma of the bladder. Results of a pilot study at Palermo University and proposal of a basic research.表柔比星与干扰素α-2b膀胱内序贯联合治疗浅表性膀胱移行细胞癌患者。巴勒莫大学一项初步研究的结果及基础研究建议。
Prog Clin Biol Res. 1991;370:185-93.
2
A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group.
Br J Urol. 1995 Dec;76(6):697-701. doi: 10.1111/j.1464-410x.1995.tb00759.x.
3
Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-alpha-2b combined with epirubicin: a pilot study.
Urol Res. 1993;21(5):353-7. doi: 10.1007/BF00296836.
4
A pilot study comparing different dose levels and administration schedules of interferon-alpha 2b combined with epirubicin for prevention of recurrence in bladder cancer.一项比较干扰素α-2b与表柔比星不同剂量水平及给药方案预防膀胱癌复发的前瞻性研究。
Anticancer Drugs. 1992 May;3 Suppl 1:19-23. doi: 10.1097/00001813-199205000-00005.
5
Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma.膀胱内递增剂量α-2b干扰素在降低浅表性移行细胞癌复发率及进展方面的疗效
Br J Urol. 1998 Dec;82(6):829-34. doi: 10.1046/j.1464-410x.1998.00890.x.
6
Conservative treatment of high grade superficial bladder tumours.高级别浅表性膀胱肿瘤的保守治疗
Arch Ital Urol Androl. 2005 Dec;77(4):215-8.
7
Combined low-dose intravesical immunotherapy (BCG + interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up.膀胱内联合低剂量免疫疗法（卡介苗+干扰素α-2b）治疗浅表性膀胱移行细胞癌的五年随访
J Chemother. 2002 Apr;14(2):194-7. doi: 10.1179/joc.2002.14.2.194.
8
[BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study].[卡介苗与干扰素A预防浅表性膀胱癌复发的前瞻性随机研究]
Urologe A. 1994 Mar;33(2):133-7.
9
Intravesical interferon alfa in the treatment of superficial bladder cancer.膀胱内注射干扰素α治疗浅表性膀胱癌。
Semin Oncol. 1988 Oct;15(5 Suppl 5):10-3.
10
What is the optimal treatment strategy for T1 bladder tumors?
Eur Urol. 2010 Jan;57(1):32-4. doi: 10.1016/j.eururo.2009.10.015. Epub 2009 Oct 20.